LX2020
An investigational treatment for Arrhythmogenic Cardiomyopathy.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify LX2020 wherever you encounter it, plus the key facts at a glance.
- Generic name
- LX2020
- Development codes
- LX2020, AAVrh.10hPKP2
- Drug class
- AAV gene therapy
- Manufacturer
- Lexeo Therapeutics
- How it's taken
- One-time intravenous infusion, in a trial only
An investigational one-time gene therapy from Lexeo Therapeutics for arrhythmogenic cardiomyopathy caused by changes in the PKP2 gene[7][1].
We'll email you when the FDA acts on LX2020 and when new trials for Arrhythmogenic Cardiomyopathy open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where LX2020 fits
LX2020 is an experimental one-time gene therapy from Lexeo for arrhythmogenic cardiomyopathy caused by PKP2 variants, tested so far in 10 adults[6][1].
- No approved disease-modifying treatment for arrhythmogenic cardiomyopathy exists, Lexeo says[7].
- LX2020's results so far come from Lexeo's releases on a small study with no placebo group[3].
- People with a PKP2 variant can ask their cardiologist about gene therapy studies and whether the natural history study fits them.
How LX2020 works
Arrhythmogenic cardiomyopathy causes heart muscle to break down over time and be replaced by fat and scar tissue, which raises the risk of dangerous heart rhythms and sudden death[8]. Changes in PKP2, a gene for a protein in the desmosomes that hold heart muscle cells together, appear to be the most common genetic cause[8]. LX2020 packages a working, full-length copy of the human PKP2 gene in a modified virus shell called AAVrh10, used only to carry the gene, and is given once into a vein[7][1].
Lexeo says it is designed to raise PKP2 protein, rebuild the desmosomes and restore heart muscle cell function[7].
Clinical trial results
The Phase 1/2 study (NCT06109181) is an open-label, dose-escalation trial in adults aged 18 to 65 with arrhythmogenic cardiomyopathy and a disease-causing PKP2 variant who already have an implanted defibrillator (ICD) and frequent extra heartbeats[1]. ClinicalTrials.gov lists it as active and no longer recruiting, with an estimated primary completion in December 2026[1].
In its January 12, 2026 release, Lexeo reported that heart biopsies 3 months after dosing showed mean PKP2 protein increases of 93% at the low dose (2 participants) and 162% at the high dose (5 participants)[3]. Lexeo also reported a 22% mean improvement in runs of non-sustained ventricular tachycardia and a 14% mean improvement in premature ventricular contractions in 5 high dose participants at their latest visit, with no control group for comparison[3].
A separate Lexeo study (NCT06976606) follows untreated patients to describe the natural course of the disease[2].
Main registered trial: NCT06109181 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.
Side effects and safety
Side effects are the primary outcome of the Phase 1/2 study, counted at 12 months[1]. Lexeo reported in November 2025 that 1 participant in the high dose group had a serious episode of sustained ventricular tachycardia, a fast and dangerous heart rhythm, 3 months after dosing, judged possibly related to treatment; the participant was treated with heart rhythm medicine and discharged with no further intervention[6].
Lexeo reported in January 2026 that 5 high dose participants had liver test elevations; 3 were managed by restarting low-dose prednisone, a steroid, and 2 by raising prednisone and sirolimus, an immune-suppressing medicine, and all resolved without complication or hospitalization[3]. Lexeo also reported that there was no clinically significant complement activation, an immune reaction seen with some gene therapies, and that no participant had stopped the study[3].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking LX2020
Given once as an intravenous infusion in the trial[1]. Lexeo tested a low dose of 2x10^13 vg/kg in 3 participants and a high dose of 6x10^13 vg/kg in 7[6]. Any approved dose would be set by an FDA label.
Development history
ClinicalTrials.gov lists the Phase 1/2 study as starting on February 29, 2024[1]. By November 2025 all 10 participants had been dosed[6]. The FDA granted Regenerative Medicine Advanced Therapy designation in August 2026, adding to Orphan Drug and Fast Track designations[4]. In its August 12, 2026 results, Lexeo said it planned a 12-month data update for all high dose participants in the fourth quarter of 2026 and FDA engagement in 2026[5]. Lexeo has not announced a pivotal study design for LX2020.
Access and eligibility
Not approved, so it is available only in a trial. The Phase 1/2 study is no longer recruiting; it enrolled adults aged 18 to 65 with a PKP2 variant, an ICD placed at least 12 weeks earlier and a left ventricle pumping fraction of 40% or more[1]. Lexeo's natural history study (NCT06976606), which gives no treatment, is recruiting adults aged 18 to 65 with PKP2 arrhythmogenic cardiomyopathy who already have an ICD[2].
Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.
Explore Arrhythmogenic Cardiomyopathy trials
Common questions about LX2020
▸What is LX2020?
An investigational one-time gene therapy from Lexeo Therapeutics for arrhythmogenic cardiomyopathy caused by changes in the PKP2 gene[7][1]. It is being tested in a Phase 1/2 study of 10 adults, and Lexeo has reported early results only in its own releases; no paper has been published[3][1]. The FDA has given it Orphan Drug, Fast Track and Regenerative Medicine Advanced Therapy designations[4].
▸How does LX2020 work?
Arrhythmogenic cardiomyopathy causes heart muscle to break down over time and be replaced by fat and scar tissue, which raises the risk of dangerous heart rhythms and sudden death[8]. Changes in PKP2, a gene for a protein in the desmosomes that hold heart muscle cells together, appear to be the most common genetic cause[8]. LX2020 packages a working, full-length copy of the human PKP2 gene in a modified virus shell called AAVrh10, used only to carry the gene, and is given once into a vein[7][1]. Lexeo says it is designed to raise PKP2 protein, rebuild the desmosomes and restore heart muscle cell function[7].
▸What are the side effects of LX2020?
Side effects are the primary outcome of the Phase 1/2 study, counted at 12 months[1]. Lexeo reported in November 2025 that 1 participant in the high dose group had a serious episode of sustained ventricular tachycardia, a fast and dangerous heart rhythm, 3 months after dosing, judged possibly related to treatment; the participant was treated with heart rhythm medicine and discharged with no further intervention[6]. Lexeo reported in January 2026 that 5 high dose participants had liver test elevations; 3 were managed by restarting low-dose prednisone, a steroid, and 2 by raising prednisone and sirolimus, an immune-suppressing medicine, and all resolved without complication or hospitalization[3]. Lexeo also reported that there was no clinically significant complement activation, an immune reaction seen with some gene therapies, and that no participant had stopped the study[3].
▸How is LX2020 taken?
▸Is LX2020 FDA approved?
LX2020 is currently in phase 2 clinical trials for Arrhythmogenic Cardiomyopathy. It has not yet received FDA approval.
▸Is LX2020 FDA approved?
No. LX2020 is an experimental gene therapy in a Phase 1/2 study, and the FDA has not approved it for any use.
Designations: Orphan Drug, Fast Track and Regenerative Medicine Advanced Therapy.
Next: Lexeo planned a 12-month update on the high dose group in the fourth quarter of 2026.
Source: Lexeo, August 12, 2026
▸What results has LX2020 shown?
Lexeo reported that heart biopsies showed PKP2 protein rose by an average of 162% in 5 high dose participants 3 months after dosing.
Heart rhythm: Lexeo reported mean improvements of 22% in runs of fast heartbeats and 14% in extra heartbeats in the high dose group, with no control group.
Safety: One serious episode of ventricular tachycardia judged possibly related, and liver test rises in 5 people that resolved with steroid changes.
Source: Lexeo, January 12, 2026
▸Can I join an LX2020 trial?
Not right now. ClinicalTrials.gov lists the LX2020 Phase 1/2 study as active and no longer recruiting.
Who it enrolled: Adults 18 to 65 with a PKP2 variant and an implanted defibrillator.
Other option: Lexeo's natural history study, which gives no treatment, is recruiting.
Source: ClinicalTrials.gov NCT06109181
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- ClinicalTrials.gov. A Phase 1/2 Study of the Safety and Efficacy of LX2020 Gene Therapy in Patients With Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant. https://clinicaltrials.gov/study/NCT06109181
- ClinicalTrials.gov. A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM. https://clinicaltrials.gov/study/NCT06976606
- Lexeo Therapeutics, via BioSpace · 2026-01-12. Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy. https://www.biospace.com/press-releases/lexeo-therapeutics-announces-positive-interim-phase-i-ii-data-for-lx2020-for-the-treatment-of-pkp2-associated-arrhythmogenic-cardiomyopathy
- Lexeo Therapeutics, via BioSpace · 2026-08-05. Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy. https://www.biospace.com/press-releases/lexeo-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-lx2020-for-the-treatment-of-pkp2-arrhythmogenic-cardiomyopathy
- Lexeo Therapeutics, via BioSpace · 2026-08-12. Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights. https://www.biospace.com/press-releases/lexeo-therapeutics-reports-second-quarter-2026-financial-results-and-operational-highlights
- Lexeo Therapeutics, via BioSpace · 2025-11-05. Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights. https://www.biospace.com/press-releases/lexeo-therapeutics-reports-third-quarter-2025-financial-results-and-operational-highlights
- Lexeo Therapeutics. LX2020 - Lexeo Therapeutics. https://www.lexeotx.com/programs/cardiac-programs/arrhythmogenic-cardiomyopathy/
- MedlinePlus, National Library of Medicine. Arrhythmogenic right ventricular cardiomyopathy: MedlinePlus Genetics. https://medlineplus.gov/genetics/condition/arrhythmogenic-right-ventricular-cardiomyopathy/